论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Shao LD, Peng QQ, Du KX, He JY, Dong YP, Lin XY, Li JL, Wu JX
Received 18 April 2017
Accepted for publication 12 June 2017
Published 29 June 2017 Volume 2017:9 Pages 249—258
DOI https://doi.org/10.2147/CMAR.S139889
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 2
Editor who approved publication: Professor Kenan Onel
Abstract: The tumor cell (TC) PD-L1 expression has been reported by several
studies in various types of cancer, and it reduces the cytotoxicity of T-cells
toward cancer and evades the anticancer immune response. Herein, our study
focuses on the impact of PD-L1 expression in prognosis and the correlation with
clinical prognostic factors for local advanced rectal cancer with neoadjuvant
radiotherapy (RT). A total of 68 rectal cancer patients treated with
neoadjuvant RT were retrospectively enrolled in the present study. PD-L1 expression
was investigated using immunohistochemistry. A regression model was used to
identify prognostic factors associated with the disease-free survival, the
local recurrence-free survival (LRFS), and the overall survival rates. The
median follow-up was 32.5 months. Seven patients presented TC PD-L1
positive (TC PD-L1+), while the others were TC PD-L1 negative (TC PD-L1–). TC
PD-L1+ patients showed frequent tumor recurrence than TC PD-L1– patients.
Several patients with TC PD-L1– underwent long-course RT. TC PD-L1 expression
was similar to interstitial cell (IC) PD-L1 expression, and the relationship
between IC PD-L1 and pathological T stage was observed. TC PD-L1+ was related
to poor LRFS. The multivariate analysis showed TC PD-L1+ as an independent
negative prognostic factor for LRFS. In conclusion, TC PD-L1 expression
putatively predicts the LRFS for patients with rectal cancer following
neoadjuvant RT. The patients with TC PD-L1+ are susceptible to high local
recurrent rate, thereby proposing a novel immunotherapeutic strategy for PD-L1
inhibition-mediated control.
Keywords: PD-L1, rectal
cancer, neoadjuvant radiotherapy, prognosis